Journal of Ophthalmology / 2018 / Article / Tab 3

Clinical Study

Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial

Table 3

Summary of adverse events.

Safety population () (%)

Serious adverse events (SAEs)
Nonfatal APTC ATE events (not related to trial treatment)1 (4.2)
  Stroke1 (4.2)
Other nonfatal SAEs1 (4.2)
  Systemic (nonocular; not related to trial treatment)
  Lung neoplasm surgery1 (4.2)

Adverse events (AEs)
Nonserious ocular AEs (not related to trial treatment)5 (20.8)
  Keratitis2 (8.3)
  Vitreous detachment2 (8.3)
  Aggravated cataract1 (4.2)
  Epiretinal membrane1 (4.2)
  Hyposphagma1 (4.2)
  Increased intraocular pressure1 (4.2)
Nonserious systemic (nonocular) AEs (not related to trial treatment)9 (37.5)
  Bronchitis2 (8.3)

APTC ATE: antiplatelet trialists’ collaboration arteriothrombolic event. AEs experienced by >1 patient presented.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.